| 16-Bromoepiandrosterone | The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Echothiophate. | Investigational |
| 19-norandrostenedione | The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate. | Experimental, Illicit |
| 5-androstenedione | The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Echothiophate. | Experimental, Illicit |
| Acebutolol | Echothiophate may increase the bradycardic activities of Acebutolol. | Approved |
| Acetylcholine | The risk or severity of adverse effects can be increased when Echothiophate is combined with Acetylcholine. | Approved |
| Aclidinium | The therapeutic efficacy of Aclidinium can be decreased when used in combination with Echothiophate. | Approved |
| Alclometasone | The risk or severity of adverse effects can be increased when Alclometasone is combined with Echothiophate. | Approved |
| Aldosterone | The risk or severity of adverse effects can be increased when Aldosterone is combined with Echothiophate. | Experimental |
| Alprenolol | Echothiophate may increase the bradycardic activities of Alprenolol. | Approved, Withdrawn |
| Amcinonide | The risk or severity of adverse effects can be increased when Amcinonide is combined with Echothiophate. | Approved |
| Androstenedione | The risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Echothiophate. | Experimental, Illicit |
| Anecortave | The risk or severity of adverse effects can be increased when Anecortave is combined with Echothiophate. | Investigational |
| Anisotropine Methylbromide | The therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Echothiophate. | Approved |
| Arecoline | The risk or severity of adverse effects can be increased when Echothiophate is combined with Arecoline. | Experimental |
| Arotinolol | Echothiophate may increase the bradycardic activities of Arotinolol. | Approved |
| Atenolol | Echothiophate may increase the bradycardic activities of Atenolol. | Approved |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Echothiophate. | Approved |
| Atropine | The therapeutic efficacy of Atropine can be decreased when used in combination with Echothiophate. | Approved, Vet Approved |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Echothiophate. | Approved, Investigational |
| Befunolol | Echothiophate may increase the bradycardic activities of Befunolol. | Experimental |
| Benactyzine | The therapeutic efficacy of Benactyzine can be decreased when used in combination with Echothiophate. | Withdrawn |
| Benzatropine | The therapeutic efficacy of Benzatropine can be decreased when used in combination with Echothiophate. | Approved |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Echothiophate. | Approved, Vet Approved |
| Betaxolol | Echothiophate may increase the bradycardic activities of Betaxolol. | Approved |
| Bethanechol | The risk or severity of adverse effects can be increased when Echothiophate is combined with Bethanechol. | Approved |
| Bevantolol | Echothiophate may increase the bradycardic activities of Bevantolol. | Approved |
| Biperiden | The therapeutic efficacy of Biperiden can be decreased when used in combination with Echothiophate. | Approved |
| Bisoprolol | Echothiophate may increase the bradycardic activities of Bisoprolol. | Approved |
| Bopindolol | Echothiophate may increase the bradycardic activities of Bopindolol. | Approved |
| Bucindolol | Echothiophate may increase the bradycardic activities of Bucindolol. | Investigational |
| Budesonide | The risk or severity of adverse effects can be increased when Budesonide is combined with Echothiophate. | Approved |
| Bufuralol | Echothiophate may increase the bradycardic activities of Bufuralol. | Experimental, Investigational |
| Bupranolol | Echothiophate may increase the bradycardic activities of Bupranolol. | Approved |
| Carbachol | The risk or severity of adverse effects can be increased when Echothiophate is combined with Carbachol. | Approved |
| Carteolol | Echothiophate may increase the bradycardic activities of Carteolol. | Approved |
| Carvedilol | Echothiophate may increase the bradycardic activities of Carvedilol. | Approved, Investigational |
| Celiprolol | Echothiophate may increase the bradycardic activities of Celiprolol. | Approved, Investigational |
| Cevimeline | The risk or severity of adverse effects can be increased when Echothiophate is combined with Cevimeline. | Approved |
| Chlorphenoxamine | The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Echothiophate. | Withdrawn |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Echothiophate. | Approved, Investigational |
| Clobetasol | The risk or severity of adverse effects can be increased when Clobetasol is combined with Echothiophate. | Investigational |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Echothiophate. | Approved |
| Clocortolone | The risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate. | Approved |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Echothiophate. | Approved |
| Cyclopentolate | The therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Echothiophate. | Approved |
| Darifenacin | The therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate. | Approved, Investigational |
| Desloratadine | The therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate. | Approved, Investigational |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Echothiophate. | Approved |
| Desoxycorticosterone Pivalate | The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Echothiophate. | Experimental, Vet Approved |
| Dexamethasone | The risk or severity of adverse effects can be increased when Dexamethasone is combined with Echothiophate. | Approved, Investigational, Vet Approved |
| Dexetimide | The therapeutic efficacy of Dexetimide can be decreased when used in combination with Echothiophate. | Withdrawn |
| Dicyclomine | The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate. | Approved |
| Diflorasone | The risk or severity of adverse effects can be increased when Diflorasone is combined with Echothiophate. | Approved |
| Difluocortolone | The risk or severity of adverse effects can be increased when Difluocortolone is combined with Echothiophate. | Approved |
| Difluprednate | The risk or severity of adverse effects can be increased when Difluprednate is combined with Echothiophate. | Approved |
| Dipyridamole | The therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole. | Approved |
| Epibatidine | The risk or severity of adverse effects can be increased when Echothiophate is combined with EPIBATIDINE. | Experimental |
| Equilenin | The risk or severity of adverse effects can be increased when Equilenin is combined with Echothiophate. | Experimental |
| Equilin | The risk or severity of adverse effects can be increased when Equilin is combined with Echothiophate. | Approved |
| Esmolol | Echothiophate may increase the bradycardic activities of Esmolol. | Approved |
| Estrone | The risk or severity of adverse effects can be increased when Estrone is combined with Echothiophate. | Approved |
| Estrone sulfate | The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Echothiophate. | Approved |
| Ethopropazine | The therapeutic efficacy of Ethopropazine can be decreased when used in combination with Echothiophate. | Approved |
| Fesoterodine | The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate. | Approved |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Echothiophate. | Approved |
| Flumethasone | The risk or severity of adverse effects can be increased when Flumethasone is combined with Echothiophate. | Approved, Vet Approved |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Echothiophate. | Approved, Investigational |
| Fluocinolone Acetonide | The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Echothiophate. | Approved, Investigational, Vet Approved |
| Fluocinonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Echothiophate. | Approved, Investigational |
| Fluocortolone | The risk or severity of adverse effects can be increased when Fluocortolone is combined with Echothiophate. | Approved, Withdrawn |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Echothiophate. | Approved |
| Fluprednidene | The risk or severity of adverse effects can be increased when Fluprednidene is combined with Echothiophate. | Approved, Withdrawn |
| Flurandrenolide | The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Echothiophate. | Approved |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Echothiophate. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Echothiophate. | Approved |
| Formestane | The risk or severity of adverse effects can be increased when Formestane is combined with Echothiophate. | Approved, Investigational, Withdrawn |
| Gallamine Triethiodide | The therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Echothiophate. | Approved |
| Glycopyrronium | The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Echothiophate. | Approved, Investigational, Vet Approved |
| GTS-21 | The risk or severity of adverse effects can be increased when Echothiophate is combined with GTS-21. | Investigational |
| HE3286 | The risk or severity of adverse effects can be increased when HE3286 is combined with Echothiophate. | Investigational |
| Hexamethonium | The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Echothiophate. | Experimental |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate. | Approved, Vet Approved |
| Hyoscyamine | The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Echothiophate. | Approved |
| Indenolol | Echothiophate may increase the bradycardic activities of Indenolol. | Withdrawn |
| Ipratropium bromide | The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate. | Approved |
| Labetalol | Echothiophate may increase the bradycardic activities of Labetalol. | Approved |
| Landiolol | Echothiophate may increase the bradycardic activities of Aop200704. | Investigational |
| Levobunolol | Echothiophate may increase the bradycardic activities of Levobunolol. | Approved |
| Lobeline | The risk or severity of adverse effects can be increased when Echothiophate is combined with Lobeline. | Investigational |
| ME-609 | The risk or severity of adverse effects can be increased when ME-609 is combined with Echothiophate. | Investigational |
| Mecamylamine | The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate. | Approved |
| Medrysone | The risk or severity of adverse effects can be increased when Medrysone is combined with Echothiophate. | Approved |
| Methacholine | The risk or severity of adverse effects can be increased when Echothiophate is combined with Methacholine. | Approved |
| Methantheline | The therapeutic efficacy of Methantheline can be decreased when used in combination with Echothiophate. | Approved |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate. | Approved, Vet Approved |
| Metipranolol | Echothiophate may increase the bradycardic activities of Metipranolol. | Approved |
| Metixene | The therapeutic efficacy of Metixene can be decreased when used in combination with Echothiophate. | Approved |
| Metoprolol | Echothiophate may increase the bradycardic activities of Metoprolol. | Approved, Investigational |
| Mivacurium | Echothiophate may decrease the neuromuscular blocking activities of Mivacurium. | Approved |
| Mometasone | The risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate. | Approved, Vet Approved |
| Nadolol | Echothiophate may increase the bradycardic activities of Nadolol. | Approved |
| NCX 1022 | The risk or severity of adverse effects can be increased when NCX 1022 is combined with Echothiophate. | Investigational |
| Nicotine | The risk or severity of adverse effects can be increased when Echothiophate is combined with Nicotine. | Approved |
| Oleoyl-estrone | The risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Echothiophate. | Investigational |
| Orphenadrine | The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Echothiophate. | Approved |
| Oxprenolol | Echothiophate may increase the bradycardic activities of Oxprenolol. | Approved |
| Oxybutynin | The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Echothiophate. | Approved, Investigational |
| Oxyphenonium | The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Echothiophate. | Approved |
| Pancuronium | The therapeutic efficacy of Pancuronium can be decreased when used in combination with Echothiophate. | Approved |
| Paramethasone | The risk or severity of adverse effects can be increased when Paramethasone is combined with Echothiophate. | Approved |
| Penbutolol | Echothiophate may increase the bradycardic activities of Penbutolol. | Approved, Investigational |
| Pentolinium | The therapeutic efficacy of Pentolinium can be decreased when used in combination with Echothiophate. | Approved |
| Pilocarpine | The risk or severity of adverse effects can be increased when Echothiophate is combined with Pilocarpine. | Approved |
| Pindolol | Echothiophate may increase the bradycardic activities of Pindolol. | Approved |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate. | Approved |
| Pirenzepine | The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Echothiophate. | Approved |
| Practolol | Echothiophate may increase the bradycardic activities of Practolol. | Approved |
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Echothiophate. | Approved, Nutraceutical |
| Prasterone sulfate | The risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Echothiophate. | Investigational |
| Prednicarbate | The risk or severity of adverse effects can be increased when Prednicarbate is combined with Echothiophate. | Approved |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate. | Approved, Vet Approved |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Echothiophate. | Approved, Vet Approved |
| Pregnenolone | The risk or severity of adverse effects can be increased when Pregnenolone is combined with Echothiophate. | Experimental |
| Procyclidine | The therapeutic efficacy of Procyclidine can be decreased when used in combination with Echothiophate. | Approved |
| Propantheline | The therapeutic efficacy of Propantheline can be decreased when used in combination with Echothiophate. | Approved |
| Propiverine | The therapeutic efficacy of Propiverine can be decreased when used in combination with Echothiophate. | Investigational |
| Propranolol | Echothiophate may increase the bradycardic activities of Propranolol. | Approved, Investigational |
| Quinidine | The therapeutic efficacy of Quinidine can be decreased when used in combination with Echothiophate. | Approved |
| Rapacuronium | Echothiophate may decrease the neuromuscular blocking activities of Rapacuronium. | Withdrawn |
| Rimexolone | The risk or severity of adverse effects can be increased when Rimexolone is combined with Echothiophate. | Approved |
| Scopolamine | The therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate. | Approved |
| Scopolamine butylbromide | The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Echothiophate. | Approved, Vet Approved |
| Solifenacin | The therapeutic efficacy of Solifenacin can be decreased when used in combination with Echothiophate. | Approved |
| Sotalol | Echothiophate may increase the bradycardic activities of Sotalol. | Approved |
| Succinylcholine | The serum concentration of Succinylcholine can be increased when it is combined with Echothiophate. | Approved |
| Timolol | Echothiophate may increase the bradycardic activities of Timolol. | Approved |
| Tiotropium | The therapeutic efficacy of Tiotropium can be decreased when used in combination with Echothiophate. | Approved |
| Tixocortol | The risk or severity of adverse effects can be increased when Tixocortol is combined with Echothiophate. | Approved |
| Tolterodine | The therapeutic efficacy of Tolterodine can be decreased when used in combination with Echothiophate. | Approved, Investigational |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Echothiophate. | Approved, Vet Approved |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Echothiophate. | Approved |
| Trimethaphan | The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Echothiophate. | Approved |
| Tropicamide | The therapeutic efficacy of Tropicamide can be decreased when used in combination with Echothiophate. | Approved |
| Trospium | The therapeutic efficacy of Trospium can be decreased when used in combination with Echothiophate. | Approved |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Echothiophate. | Approved |
| Umeclidinium | The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Echothiophate. | Approved |
| Varenicline | The risk or severity of adverse effects can be increased when Echothiophate is combined with Varenicline. | Approved, Investigational |
| Vecuronium | The therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate. | Approved |
